Products with Hemolytic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3241 | Platycoside A |
| 1. Platycoside A induces the IgG and IgG1 antibody responses in the immunized mice. 2. Platycoside A has hemolytic activity and adjuvant potential on the immune responses to Newcastle disease virus-based recombinant avian influenza vaccine. | |
| BCN3503 | Ginsenoside Rh4 |
| Ginsenoside Rh4 is a rare saponin obtained from Panax notoginseng. Ginsenoside Rh4 activates Bax, caspase 3, caspase 8, and caspase 9. Ginsenoside Rh4 also induces autophagy. Ginsenoside Rh4 could be safely used as adjuvant with low or non-haemolytic effect; it has cytotoxic activity and its aglycone against cancer cell lines. | |
| BCN3847 | Platycodin D2 |
| 1. Platycodin D2 , a less hemolytic saponin, can improve specific cellular and humoral responses to hepatitis B surface antigen in mice. 2. Platycodin D2 could be safely used as adjuvant eliciting Th1 and Th2 immune responses. 3. Polygalacin D2 exhibits significant inhibition on the proliferation of five kinds of cultured human tumor cell lines, i. e., A549 (non-small cell lung), SK-OV-3 (ovary), SK-MEL-2 (melanoma), XF498 (central nerve system) and HCT-15 (colon), in vitro. | |
| BCN3893 | Medicagenic acid |
| 1. Medicagenic acid derivatives exhibit potent fungistatic effects against several plant pathogens and human dermatophytes. 2. Medicagenic acid, the factor responsible for hemolytic activity of lucerne saponins. | |
| BCN5010 | Esculentoside A |
| Esculentoside A has anti-inflammatory activity , can suppress inflammatory responses in LPS-induced ALI through inhibition of the nuclear factor kappa B and mitogen activated protein kinase signaling pathways. Esculentoside A may be useful for the treatment of autoimmune disease through modulation on T cell-mediated adaptive immunity. Esculentoside A treatment can attenuate CCl4 and GalN/LPS-induced acute liver injury in mice. | |
